Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: Results of a phase II study

被引：44

作者：

Constenla M. ^{[1
]}

Garcia-Arroyo R. ^{[1
]}

Lorenzo I. ^{[1
]}

Carrete N. ^{[1
]}

Campos B. ^{[1
]}

Palacios P. ^{[1
]}

机构：

[1] Medical Oncology Service, Complexo Hospitalario de Pontevedra, 36001 Pontevedra, C/Loureiro Crespo

来源：

Gastric Cancer | 2002年 / 5卷 / 3期

关键词：

5-Fluorouracil; Docetaxel; Leucovorin; Phase II; Taxane;

D O I：

10.1007/s101200200025

中图分类号：

学科分类号：

摘要：

Background. Previous studies have shown that the taxane, docetaxel, is effective in treating gastric cancer. The aim of this study was to assess the efficacy and safety of docetaxel in combination with 5-fluorouracil (5-FU) and leucovorin (LV). Methods. Thirty patients with histologically proven locally advanced and/or metastatic gastric cancer with WHO performance status 0-2 were enrolled and received either 75 or 100 mg/m2 docetaxel as a 1-h intravenous infusion on day 1 every 28 days. All patients also received 5-FU (1800 mg/m2) plus LV (500 mg/m2), by continuous intravenous infusion over 24h on days 1, 8, and 15 every 28 days. Chemotherapy was given for at least two cycles. Results. Of the 25 evaluable patients, 3 showed a complete response, 4 showed a partial response, and 11 patients had stable disease. The overall response rate was 28.0% (95% confidence interval [CI], 10.4, 45.6). The median time to progression was 5.9 months (95% CI, 5.4, 6.5), and the median overall survival was 7.7 months (95% CI, 7.2, 8.3) for the intent-to-treat population. The most frequent grade III and IV hematological toxicities were neutropenia and anemia. Febrile neutropenia was observed in 10% of patients and 2.4% of cycles. The prophylactic use of granulocyte colony-stimulating factor (G-CSF) in 3 patients reduced the incidence and severity of neutropenia. Other hematological toxicities were rare. Conclusion. Docetaxel in combination with weekly 5-FU and LV is effective in treating patients with advanced/metastatic gastric cancer. This new docetaxel-containing combination shows promise as a third-generation treatment option for gastric cancer. © 2002 by International and Japanese Gastric Cancer Associations.

引用

页码：142 / 147

页数：5

共 27 条

[1]

Kohne C.H., Wils J.A., Wilke H.J., Developments in the treatment of gastric cancer in Europe, Oncology (Huntingt), 14, pp. 22-25, (2000)

[2]

Hill M.E., Cunningham D., Medical management of advanced gastric cancer, Cancer Treat Rev, 24, pp. 113-118, (1998)

[3]

Kelsen D., Chemotherapy of gastric cancer: A review, Isr J Med Sci, 24, pp. 557-561, (1988)

[4]

Rougier P., Wils J., Wilke H., Advanced gastric cancer: Comparison of FAMTX (5-FU + adriamycine + methotrexate) versus ELF (etoposide + 5-FU + leucovorin) versus FUP (infusional 5-FU + cisplatin). Results from an EORTC trial of the GITCCG and the Arbeitsgemeinschaft für innere Onkologie, Eur J Cancer, 31, (1995)

[5]

Cullinan S.A., Moertel C.G., Wieand H.S., O'Connell M.J., Poon M.A., Krook J.E., Et al., Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer, J Clin Oncol, 12, pp. 412-416, (1994)

[6]

Roth A.D., Maibach R., Martinelli G., Fazio N., Aapro M.S., Pagani O., Et al., Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma, Ann Oncol, 11, pp. 301-306, (2000)

[7]

Webb A., Cunningham D., Scarffe J.H., Harper P., Norman A., Joffe J.K., Et al., Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer, J Clin Oncol, 15, pp. 261-267, (1997)

[8]

Cascinu S., Labianca R., Alessandroni P., Marcellini M., Silva R.R., Pancera G., Et al., Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer, J Clin Oncol, 15, pp. 3313-3319, (1997)

[9]

Fuchs C.S., Chemotherapy for advanced gastric cancer: Where do we stand?, J Clin Oncol, 15, pp. 3299-3300, (1997)

[10]

Tanaka M., Obata T., Sasaki T., Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo, Eur J Cancer, 32 A, pp. 226-230, (1996)

← 1 2 3 →